Investment Analysts’ Recent Ratings Updates for Alnylam Pharmaceuticals (ALNY)

Posted by on Aug 10th, 2026

A number of firms have modified their ratings and price targets on shares of Alnylam Pharmaceuticals (NASDAQ: ALNY) recently:

  • 8/4/2026 – Alnylam Pharmaceuticals had its price target lowered by Truist Financial Corporation from $410.00 to $315.00. They now have a “buy” rating on the stock.
  • 8/3/2026 – Alnylam Pharmaceuticals had its price target lowered by Citigroup Inc. from $380.00 to $340.00. They now have a “buy” rating on the stock.
  • 8/3/2026 – Alnylam Pharmaceuticals was upgraded by Raymond James Financial, Inc. from “outperform” to “strong-buy”. They now have a $420.00 price target on the stock.
  • 8/3/2026 – Alnylam Pharmaceuticals had its price target lowered by Barclays PLC from $527.00 to $450.00. They now have an “overweight” rating on the stock.
  • 8/2/2026 – Alnylam Pharmaceuticals was downgraded by Wall Street Zen from “strong-buy” to “hold”.
  • 7/31/2026 – Alnylam Pharmaceuticals was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.
  • 7/31/2026 – Alnylam Pharmaceuticals had its price target lowered by HC Wainwright from $485.00 to $455.00. They now have a “buy” rating on the stock.
  • 7/31/2026 – Alnylam Pharmaceuticals had its price target lowered by Royal Bank Of Canada from $445.00 to $350.00. They now have an “outperform” rating on the stock.
  • 7/31/2026 – Alnylam Pharmaceuticals had its price target lowered by JPMorgan Chase & Co. from $400.00 to $375.00. They now have an “overweight” rating on the stock.
  • 7/31/2026 – Alnylam Pharmaceuticals had its price target lowered by Morgan Stanley from $400.00 to $300.00. They now have an “equal weight” rating on the stock.
  • 7/31/2026 – Alnylam Pharmaceuticals had its price target lowered by Oppenheimer Holdings, Inc. from $500.00 to $350.00. They now have an “outperform” rating on the stock.
  • 7/31/2026 – Alnylam Pharmaceuticals had its price target lowered by Wells Fargo & Company from $377.00 to $316.00. They now have an “equal weight” rating on the stock.
  • 7/31/2026 – Alnylam Pharmaceuticals had its price target lowered by Stifel Nicolaus from $444.00 to $318.00. They now have a “buy” rating on the stock.
  • 7/31/2026 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by Chardan Capital. They now have a $425.00 price target on the stock.
  • 7/30/2026 – Alnylam Pharmaceuticals had its price target lowered by Needham & Company LLC from $510.00 to $357.00. They now have a “buy” rating on the stock.
  • 7/29/2026 – Alnylam Pharmaceuticals was upgraded by Sanford C. Bernstein to “strong-buy”.
  • 7/25/2026 – Alnylam Pharmaceuticals was upgraded by Wall Street Zen from “buy” to “strong-buy”.
  • 7/22/2026 – Alnylam Pharmaceuticals had its price target lowered by JPMorgan Chase & Co. from $420.00 to $400.00. They now have an “overweight” rating on the stock.
  • 7/14/2026 – Alnylam Pharmaceuticals had its price target lowered by Bank of America Corporation from $460.00 to $410.00. They now have a “buy” rating on the stock.
  • 7/13/2026 – Alnylam Pharmaceuticals had its price target lowered by Truist Financial Corporation from $505.00 to $410.00. They now have a “buy” rating on the stock.
  • 7/13/2026 – Alnylam Pharmaceuticals had its price target raised by HC Wainwright from $470.00 to $485.00. They now have a “buy” rating on the stock.
  • 7/10/2026 – Alnylam Pharmaceuticals had its price target raised by Morgan Stanley from $370.00 to $400.00. They now have an “equal weight” rating on the stock.
  • 7/7/2026 – Alnylam Pharmaceuticals was downgraded by Wall Street Zen from “strong-buy” to “buy”.
  • 6/29/2026 – Alnylam Pharmaceuticals had its price target lowered by HC Wainwright from $510.00 to $470.00. They now have a “buy” rating on the stock.
  • 6/29/2026 – Alnylam Pharmaceuticals was upgraded by Wall Street Zen from “buy” to “strong-buy”.
  • 6/21/2026 – Alnylam Pharmaceuticals was downgraded by Wall Street Zen from “strong-buy” to “buy”.
  • 6/13/2026 – Alnylam Pharmaceuticals was upgraded by Wall Street Zen from “buy” to “strong-buy”.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 3,830 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $299.18, for a total value of $1,145,859.40. Following the sale, the director directly owned 1,582 shares in the company, valued at approximately $473,302.76. This trade represents a 70.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is owned by corporate insiders.

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.

Featured Stories

Receive News & Ratings for Alnylam Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.